Angle Share Discussion Threads

[havinthelasttoast] 22/3/2024 12:53

Placing coming lads ?

[iomdm] 22/3/2024 10:41

HTLT, placing you in filtered box I think!

[havinthelasttoast] 22/3/2024 10:37

Everybody sick of the newland money pit where he earns big doh every year and gets a juicy pension for nada. Got to laugh

Placing anyone ?

[riskyinvestor] 22/3/2024 10:35

Tower Resources (TRP) is the Stock to be in

[5oletrader] 22/3/2024 09:30

Re BBC article/grail/ctDNA. Some 'stuff' to ponder?-Is the Galleri test FDA approved?• The Galleri test has NOT been cleared OR approved by the FDA.Https://assets.galleri.com/statics/Downloads/Klick_Galleri_FAQs_v3-June-2023.pdf• In the US, because Galleri has NOT yet won approval from the FDA, it is NOT covered by US government health insurance schemes.-NHS-Galleri trial:• 'IF' the Galleri test does NOT WORK well in this setting, then we will still have learned important information about what research needs to be done in the FUTURE to improve cancer screening.Https://www.nhs-galleri.org/about-the-trial-Trial results and next steps:• Once the results of the trial are available, these will be shared publicly. Often this is in a science journal, press release, or on the trial website. Results are likely to be ready in 2026 but may take LONGER. Https://www.nhs-galleri.org/taking-part/what-happens-after-your-24-month-appointment#:~:text=Results%20are%20likely%20to%20be,test%20works%20in%20the%20NHS.-Interesting Article:• Not everyone is convinced the tests live up to the hype. Several health experts and scientists told the Financial Times that the tests could harm rather than help some patients due to risks associated with misdiagnosis, over-diagnosis and over-treatment.• Susan Bewley, a consultant obstetrician and emeritus professor of obstetric and women's health at King's College London, says the problem with MCED screening is that the MORE of this you DO on HEALTHY people the MORE ERRORs you get.• "This sort of screening test could bankrupt the NHS, prioritise people who are well over those who are sick, and make people ill. This is ethically dubious," says Bewley. "Before these tests are rolled out we need to follow hundreds of thousands of people over many years to determine if the treatments actually stop them from dying."• Bewley is concerned that the way the NHS trial is structured means that Grail is likely to claim success even though many of the people with early-stage cancer may never have become ill.Https://www.ft.com/content/b5aaa6a9-a5a9-44a4-a57e-5ad69babcd7b-Call me cynic - how did the 'NHS gig' come about in the first place?• Illumina and Grail increased their US lobbying spending fivefold to $14.6M• ?Illumina also expanded lobbying in Europe and the UK, where it hired former prime minister David Cameron as an adviser in 2019 shortly before winning a gene sequencing contract with a company owned by the Department of Health and Social Care.• ?In November 2020, the NHS struck its deal with Grail to pilot Galleri - a collaboration that is key to winning regulatory approval. -Why mention above? Well:• Parsortix is FDA approved.• AGL achieved breakthrough CTC & ctDNA clinical results (same blood sample.)• Assay development underway.• AN mentioned at year end providing tests FOR patients not just ABOUT. AGL to be major competition for MEDC test providers? -• Remember when Illumina bought Grail back for $8bn (deal blocked). 'PIE in the SKY'I leave you with:• The BILLION DOLLAR QUESTION - What' is AGL worth?

[gspanner] 22/3/2024 09:01

‘do offer Ctdna and Ctc from the same blood sample!’

Yes so adding CTCs much less of an issue if already taking a sample, only a small amount of lab bench space for the Parsortix machine.

The critical issue is that collecting that blood sample is now going to become routine practice for hundreds of U.K.
oncologists.

Now we just need a proven reason to harvest CTCs too (more accurate her-2/PDL1/other predictive markers for drug reposes).

[boris cobaka] 22/3/2024 08:55

Market not really paying attention to biopharma. Are the ducks starting to form a row?

At a glance peeps see the rns and perhaps think the bounce is due to that.....
Nice camo.

[boris cobaka] 22/3/2024 08:54

I think gspanner is referring to the NHS Grail study announced last year, but your point Jelenko is well made.

"Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample highlights potential for the Parsortix system to identify key variants (DNA mutations) missed by other approaches to help guide treatment decisions

The new DNA sample-to-answer molecular solution combining CTC and ctDNA analysis is expected to be a driver of product and pharma services sales'

[htrocka2] 22/3/2024 08:45

699 has gone quiet.....probably now jumped onto the sky train.

[jelenko] 22/3/2024 08:40

gspanner actually AGL do offer Ctdna and Ctc from the same blood sample!

[chester9] 22/3/2024 08:14

https://www.bbc.co.uk/news/health-68624334

[gspanner] 22/3/2024 08:09

Probably more significant than the RNS this am tbh!

[gspanner] 22/3/2024 08:09

Whilst ctDNA isn’t what Angle offer, the fact that ‘liquid biopsy’ is being embedded into a patient tumour pathway is very significant IMO. The sort of infrastructure and processes required will be established.
Live cells only needs to be a small proportion of the total assays to be very successful.

[herschel k] 22/3/2024 08:01

Thanks Bermuda

[bermudashorts] 22/3/2024 07:37

Without checking, I'm fairly certain they're talking about the Grail/NHS collaboration - a ctDNA screening programme.

[herschel k] 22/3/2024 07:33

Just listened to radio 5Big interview and discussion on it.

[herschel k] 22/3/2024 07:32

Bbc article sounds very positiveIs there any other company doing ctdna biopsies in the UK?

[kirk 6] 22/3/2024 07:31

Well this ain't the bad news the market was expecting. Could rally quite abit today

[beergut] 22/3/2024 07:30

Does anyone know if this is what the BBC Radio 4 were talking about this morning. Quite a good report on the treatment of Breast Cancer, but didn't mention the company name

[fhmktg] 22/3/2024 07:20

MrK, Bones 698
This looks like a superb area for Portrait+ to check on the influence of this particular drug on the patients disease progress.
Are you going to ask AGL or the Marsden if Parsortix is being used?

[saltraider] 22/3/2024 07:20

@Abbs ... It's OK to adopt a 'TLDR' approach. That's your own business. But I think it's a bit much to ask posters to summarise stuff just so that you can be spoon-fed.

[abbs] 22/3/2024 07:14

Mr K what’s the idiots guide summary please any new news apart for Angle doing another preenestaion?

NHS analysis for 14 day turnaround is certainly great news if it involves Angle.

[mrkeysersoze] 22/3/2024 07:04

For immediate release


22 March 2024



ANGLE plc ("the Company")



PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCE



ANGLE presenting two posters highlighting the utility of the Company's new Portrait+ CTC Staining Kit and Portrait HER2 assay





ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce its participation at the 14th European Breast Cancer Conference (EBCC) being held in Milan, Italy on 20 to 22 March 2024.



EBCC is focused on multidisciplinary, high-quality clinical and translational research, with an emphasis on innovation and technology in the management of breast cancer. The conference is attended by researchers, physicians, patient advocates and industry representatives providing sales, partnership and collaboration opportunities.



ANGLE is presenting two posters at the conference:



1. Integrating isolation using label-independent microfluidics and advanced staining for comprehensive Circulating Tumour Cell Analysis



ANGLE's Parsortix® system and Portrait®+ CTC Staining Kit together provide an optimised, efficient, and standardised solution for the harvest and characterisation, via immunofluorescence (IF) staining, of a diverse range of CTC phenotypes. In the presented data, half of the CTC-positive breast cancer patient blood samples contained only mesenchymal CTCs, while half had a combination of both epithelial and mesenchymal CTCs. Patients with purely mesenchymal CTCs would have been missed by epitope-dependent systems. This is important because mesenchymal CTCs or CTCs undergoing epithelial-to-mesenchymal transition are clinically significant, playing a critical role in cancer progression, treatment resistance and metastasis.



CTC clusters harvested by the Parsortix system were observed in 75% of the CTC-positive patients which is crucial given that CTC clusters have been shown to have up to 100 times the increased metastatic potential compared to single CTCs. The Parsortix cassette's unique design is suited to capturing and harvesting clusters which is often difficult with other CTC systems.



The study results highlight the importance of using ANGLE's Parsortix system combined with the Company's Portrait+ CTC Staining Kit, to enable the isolation and analysis of a range of CTC phenotypes and CTC clusters, both of which are important in cancer progression and metastasis.



2. Interrogating HER2 status in Circulating Tumour Cells isolated using the Parsortix® system from Metastatic Breast Cancer patients



The diagnosis and treatment of breast cancer is currently guided by the evaluation of human epidermal growth factor receptor 2 (HER2) status in tissue biopsies. However, a tissue biopsy is invasive, is at a single point in time and, with little opportunity for repeat testing, can become out of date. The longitudinal monitoring of HER2 expression from blood is possible through minimally invasive CTC-based liquid biopsy techniques. ANGLE has developed an IF assay for HER2 protein identification on CTCs isolated and harvested using the Parsortix system from the peripheral blood of metastatic breast cancer (MBC) patients.



Results from an in-house study in 26 patients found that CTCs overexpressing HER2 were present at similar levels in patients that had HER2+ or HER2- tumours by primary tissue biopsy. HER2 status of CTCs was also dynamic, changing over time in 37% of CTC positive donors which is unsurprising given that temporal changes in HER2 tissue status are also well documented in the literature. One third-party study of 575 breast cancer patients similarly found that 38% had changed HER2 status from the original primary tissue biopsy to the metastatic tissue biopsy, at disease recurrence. These initial results using Parsortix-based harvest of CTCs demonstrate how the HER2 status between primary tumours and CTCs can diverge, and that analysis of HER2 expression on CTCs has the potential to help guide clinical decision making in MBC patients, allowing for regular monitoring and tracking of treatment and/or disease progression.



ANGLE Chief Scientific Officer, Karen Miller, commented:

"We are delighted to have had two posters presented at the EBCC conference. The results of these studies further demonstrate the potential utility of ANGLE's sample-to-answer Parsortix system and Portrait imaging assays for reliable and repeatable assessment of biomarkers in a range of solid tumours, including breast. We look forward to discussions with translational researchers and industry representatives at this conference to explore opportunities for sales, collaboration, and partnerships."


Mr K.